In September 2019, MAPS raised $610,181 in new donations and pledges from 953 supporters. Of that amount, $64,312 was for general support, $519,765 for MDMA research, and $25,903 was for the Zendo Project.
Throughout August and September 2019, MAPS held its annual crowdfunding campaign for the Zendo Project, a MAPS peer support program that provides training and services for challenging psychedelic experiences. To support our annual fundraising campaign, our international community generously donated $108,418 since August 16, 2019, surpassing our $100,000 goal. Donations to the Zendo Project were doubled by matching grants provided by the Riverstyx Foundation ($30,000), Connor Hill ($15,000), and Dan McMurtrie ($10,000). We extend our gratitude to all who contributed.
Currently, MAPS estimates $10 million is needed for European Medicines Agency (EMA) Phase 3 MDMA-assisted psychotherapy for PTSD trials to supplement the data gathered for the FDA. In May 2019, MAPS reached our initial goal of $2 million raised for this program, facilitating the continuation of critical start up activities for the planned trials in multiple European countries.
We extend a special thanks to those who so generously supported MAPS last month:
- Lopker Family Foundation ($20,000)
- Michael Pollack ($5,000)
- Highfield Foundation ($2,500)
- Sam Shwartz ($2,500)
- Kirsten Waerstad ($2,500)
- Michael Pollan & Judith Beller ($2,000)
- Anonymous ($2,000)
- RollSafe.org ($1,443)
- Anonymous ($1,035)
- The Betsy Gordon Foundation ($1,000)
- Anonymous ($1,000)
- Anonymous ($5,000)
- Tyler Borland ($1,000)
- DanceSafe ($1,000)
- Rachel Hamilton ($1,000)
- Duncan Smith ($1,000)
- Lisa Waugh ($1,000)
- Anonymous ($1,000)
MDMA/PTSD Phase 3:
- Good Ventures ($500,000)
MDMA Therapy Training Program:
- Fred J. Brotherton Charitable Foundation ($10,000)
MDMA/PTSD in Israel:
- Michael & Anita Siegal Family Foundation ($4,000)
MAPS relies on the generosity of individual donors to achieve its mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.